IP Library › Granted Patent US 8,329,401
Granted Patent B2
US 8,329,401 · App. 12/608,261 · Granted Dec 11, 2012

Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest

Assignee: Ventana Medical Systems, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,401
App. No.
12/608,261
Granted
Dec 11, 2012
Kind
B2
Abstract

The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.

Claims (26)

1. A method of detecting nucleic acids of interest in a biological sample comprising the steps of:

(a) labeling DNA isolated from the biological sample with a first member of a specific binding pair;

(b) contacting the DNA of step (a) to a microarray of nucleic acid probes immobilized on a solid support;

(c) incubating the microarray of step (b) with a label enzyme conjugated to a second member of the specific binding pair, the label enzyme selected from the group consisting of alkaline phosphatase, acid phosphatase, alpha- and beta-galactosidases, alpha- and beta-glucosidases, esterases, and beta-lactamases;

(d) incubating the microarray with a redox inactive reductive species and soluble metal ions, the redox inactive reductive species being a substrate for the label enzyme so that the label enzyme converts the redox inactive reductive species to a redox active reductive species that reduces the soluble metal ions to form a metal precipitate on the microarray; and

(e) detecting DNA hybridized to the microarray by detecting the metal precipitate formed on the microarray.

2. The method of claim 1 wherein the label enzyme is alkaline phosphatase, and said redox-inactive reductive species is ascorbic acid phosphate.

3. The method of claim 1 wherein the label enzyme is alkaline phosphatase, and said redox-inactive reductive species is a hydroquinone phosphate.

4. The method of claim 1 wherein the redox-inactive reductive species is selected from the group consisting of hydroquinone mono- and di-phosphates, naphthohydroquinone mono- and di-phosphates, and anthrahydroquinone mono- and di-phosphates.

5. The method of claim 1 wherein the redox inactive reductive species is selected from the group consisting of sesamol phosphate, eugenol phosphate and alpha-tocopherol phosphate.

6. The method of claim 1 wherein the soluble metal ions are selected from the group consisting of silver ions and gold ions.

7. The method of claim 6 wherein the soluble metal ions are silver ions.

8. The method of claim 7 wherein prior to the reduction of soluble silver metal ions in step (d), the biological sample is pretreated with gold.

9. A method of detecting nucleic acids of interest in a biological sample, comprising

labeling DNA isolated from the biological sample with a first member of a specific binding pair,

contacting a nucleic acid microarray with the DNA,

contacting the microarray with an enzyme-labeled conjugate, the enzyme-labeled conjugate comprising a second member of the specific binding pair and an enzyme,

contacting the microarray with a redox-inactive reductive species that is a substrate for the enzyme and soluble metal ions, the enzyme converting the redox-inactive species to a redox-active species that reduces the soluble metal ions to an insoluble metal that precipitates at or about the point where said enzyme-labeled conjugate molecule is bound, and

detecting the insoluble metal;

wherein the enzyme is selected from the group consisting of alkaline phosphatase, acid phosphatase, alpha- and beta-galactosidases, and esterases.

10. The method of claim 9 , wherein the second member of the specific binding pair is an antibody.

11. The method of claim 9 , wherein the enzyme is selected from the group consisting of alkaline phosphatase and acid phosphatase and the redox-inactive reductive species is selected from the group consisting of hydroquinone mono- and di-phosphates, naphthohydroquinone mono- and di-phosphates, and anthrahydroquinone mono- and di-phosphates.

12. The method of claim 9 , wherein the enzyme is selected from the group consisting of alkaline phosphatase and acid phosphatase and the redox-inactive reductive species is selected from the group consisting of sesamol phosphate, eugenol phosphate and alpha-tocopherol phosphate.

13. The method of claim 9 , wherein the soluble metal ions are selected from the group consisting of silver ions and gold ions.

14. The method of claim 9 , wherein the soluble metal ions are gold ions and the method further comprises a subsequent step of contacting the microarray with the redox-inactive reductive species that is the substrate for the enzyme and silver soluble metal ions,

wherein gold metal formed at or about the point where said enzyme-labeled conjugate molecule is bound serve as nucleation sites for deposition of metallic silver.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2009
From: BIENIARZ, CHRISTOPHER; FARRELL, MICHAEL
To: VENTANA MEDICAL SYSTEMS, INC.
Reel/Frame 023521/0543 →
Continuity (4)
Continuation 11015646 · Dec 20, 2004
Continuation In Part 10877919 · Jun 24, 2004
Provisional Application 60482596 · Jun 24, 2003
Related Publication 20100105566A1 · Apr 29, 2010